Highlights

  • Star Combo develops, manufactures and distributes vitamins, dietary supplements and skincare products.
  • The company serves Australian customers and overseas markets, particularly in Asia.
  • Revenue for the six months ended 31 December 2025 was A$11,932,609, according to its half-year report.
  • Profit attributable to owners for that half-year period was A$413,243.
  • Manufacturing capacity, order volumes and distribution arrangements remain relevant operating factors.

Star Combo Pharma Limited (ASX:S66) develops, manufactures and distributes branded vitamins, dietary supplements and skincare products, with contract manufacturing services alongside its own product ranges. Its operations connect production in Australia with domestic retail channels and export markets. The FY26 reporting period provides a basis for examining how the company balances manufacturing activity, distribution and operating costs.

How the Manufacturing Model Works

The group manufactures products for third-party customers and maintains its own brands, including Costar, Living Healthy, Amax and J&K. The product mix encompasses supplements and skincare, rather than prescription-drug research or clinical therapeutics. For Star Combo Pharma Limited (ASX:S66), production scheduling, quality control and customer orders are central to the manufacturing model.

Its Smithfield operations are supported by manufacturing capabilities and product-development services. As a regulated participant in complementary health product manufacturing, the group must comply with applicable manufacturing and product standards. This creates operational requirements around processes, documentation and quality assurance.

What the FY26 Half-Year Accounts Reported

For the six months ended 31 December 2025, Star Combo Pharma Limited (ASX:S66) reported revenue of A$11,932,609 and profit after tax attributable to owners of A$413,243. Total comprehensive income attributable to shareholders was A$466,409. These amounts are drawn from its half-year financial statements released on 25 February 2026 and should be read as half-year results, not full-year totals.

Revenue and profit moved in different directions relative to the previous corresponding half-year period. The report recorded a 24% decline in revenue and a 49% increase in profit attributable to owners. These results illustrate why turnover and profitability must be assessed separately: revenue measures sales activity, while final profit also reflects the effect of costs and other accounting items.

The board did not recommend a dividend for the half-year period. Star Combo Pharma Limited (ASX:S66) also reported net tangible asset backing of A$0.28 per ordinary share at 31 December 2025. This is a balance-sheet measure rather than an indication of trading performance or future distributions.

Warehouse Investment and Operating Considerations

In an April 2026 company update, Star Combo described an upgrade to its Australian warehouse operations. Warehousing sits alongside manufacturing and distribution in the group’s supply chain: stock handling and fulfilment affect the movement of finished products to customers. The existence of an upgrade does not itself establish measurable savings, additional sales or improved margins without supporting operating disclosures.

For Star Combo Pharma Limited (ASX:S66), the principal business considerations include customer demand, capacity utilisation, raw material procurement, manufacturing compliance and the costs of maintaining domestic and export distribution. Foreign-market activity can also introduce logistics and currency exposure. The financial effect of these factors depends on actual orders, cost conditions and reported results.

Key Insights

Star Combo Pharma Limited (ASX:S66) combines contract manufacturing, owned supplement brands and distribution functions within one business. Its FY26 half-year statements show lower revenue alongside higher attributable profit, making cost structure and earnings composition relevant to understanding performance. Subsequent company disclosures provide the appropriate basis for assessing whether manufacturing and warehouse initiatives are reflected in financial outcomes.